Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
University of New Mexico
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00003585CT.gov Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer | — | Completed | — | — | — |
NCT00002737CT.gov Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Isotretinoin (this asset) | University of New Mexico | P3 | CCC · 53 |
| Alpha-Interferon | Dartmouth-Hitchcock Medical Center | P3 | BBB |
| Girentuximab | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Etoposide | City of Hope Medical Center | P3 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Fluorouracilum | Medical Research Council | P3 | BB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BB |
| Lenvatinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Catequentinib | Fudan University | P3 | BB |
+42 more in the Kidney Cancer cohort
Other indications for Isotretinoin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Neoplasm | — | P3 | B · 59 |
| Brain Neoplasm | — | P3 | CCC · 55 |
| Glioblastoma | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Isotretinoin in Kidney Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/isotretinoin-kidney-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →